Search Results - "Steino, A."

Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming GBM chemoresistance by Steino, A, Zhai, B, Daugaard, M, Brown, D, Bacha, J, Golebiewska, A, Niclou, S

“…Glioblastoma (GBM) is the most aggressive malignant brain cancer. The heterogeneous nature of GBM tumors and highly chemoresistant cancer stem-cells (CSCs)…”
Get full text

363 - Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming GBM chemoresistance by Steino, A., Zhai, B., Daugaard, M., Brown, D., Bacha, J., Golebiewska, A., Niclou, S.

Get full text

P08.57 Distinct mechanism-of-action of dianhydrogalactitol (VAL-083) overcomes chemoresistance in glioblastoma by Zhai, B., Gobielewska, A., Steino, A., Bacha, J. A., Brown, D. M., Niclou, S., Daugaard, M.

“…Standard treatments for glioblastoma (GBM) include surgery, radiation and chemotherapy with temozolomide (TMZ). Nearly all tumors recur and 5-year survival is…”
Get full text

P08.47 Dianhydrogalactitol (VAL-083) causes bifunctional alkylation leading to irreparable DNA double-strand breaks, S/G2 phase cell-cycle arrest and tumor cell death in an MGMT independent manner offering a unique treatment paradigm for GBM by Zhai, B., Steino, A., Bacha, J. A., Brown, D. M., Daugaard, M.

“…Glioblastoma (GBM) is the most common brain cancer. Systemic therapy with temozolomide or nitrosoureas is often ineffective due to the activity of the DNA…”
Get full text

Interaction of the chaperone calreticulin with proteins and peptides of different structural classes by Duus, K, Sandhu, N, Jørgensen, C S, Hansen, P R, Steinø, A, Thaysen-Andersen, M, Højrup, P, Houen, G

“…The interaction of calreticulin with native and denatured forms and polypeptides in proteolytic digests of proteins representing structural classes of…”
Get more information

P09.57 Clinical trials of VAL-083 in patients with chemoresistant glioblastoma by Bacha, J. A., Steino, A., Schwartz, R., Langlands, J., Kanekal, S., Lopez, L. M., Brown, D. M.

“…Glioblastoma (GBM) is the most common CNS tumor. Patients with recurrent GBM have few treatment options and dismal prognosis. O 6…”
Get full text

Interaction of C1q with the Receptor Calreticulin Requires a Conformational Change in C1q by Steinø, A., Jørgensen, C. S., Laursen, I., Houen, G.

“…The interaction between C1q and the chaperone calreticulin was studied under various conditions. When both proteins were present in equal amounts in solution,…”
Get full text

PO-014 Dianhydrogalactitol (vaL-083) reduces glioblastoma tumour progression in vivo, upon bevacizumab-induced hypoxia by Golebiewska, A., Oudin, A., Steino, A., Bacha, J.A., Brown, D.M., Niclou, S.P.

“…Standard-of-care for glioblastoma (GBM) includes surgery, radiation and temozolomide. Nearly all tumours recur and 5 year survival is less than 3%, largely due…”
Get full text

ET-18 VAL-083 IS A NOVEL N7 ALKYLATING AGENT THAT INHIBITS THE GROWTH OF GLIOMA STEM AND NON-STEM CULTURES, INCLUDING TEMOZOLOMIDE-RESISTANT LINES by Fouse, S., Steino, A., Butowski, N., Bacha, J., Brown, D., Costello, J.

“…The standard of care for glioblastoma multiforme (GBM) patients is surgical resection followed by temozolomide (TMZ) and radiation (XRT). TMZ is most effective…”
Get full text

AT-53 PHASE I/II STUDY OF DIANHYDROGALACTITOL IN PATIENTS WITH RECURRENT MALIGNANT GLIOBLASTOMA MULTIFORME (GBM) by Shih, K., Patel, M., Butowski, N., Bacha, J., Brown, D., Garner, W., Steino, A., Schwartz, R., Kanekal, S., Lopez, L., Burris, H. A.

“…Median survival for patients with recurrent GBM is <6 months. Front-line systemic therapy is temozolomide but resistance due to…”
Get full text

Dimerization and oligomerization of the chaperone calreticulin by Jørgensen, Charlotte S., Ryder, L. Rebekka, Steinø, Anne, Højrup, Peter, Hansen, Jesper, Beyer, N. Helena, Heegaard, Niels H. H., Houen, Gunnar

“…The chaperone calreticulin is a highly conserved eukaryotic protein mainly located in the endoplasmic reticulum. It contains a free cysteine SH group but does…”
Get full text